Aclaris Therapeutics, Inc. (ACRS)
6.31
-0.10
(-1.56%)
USD |
NASDAQ |
Aug 24, 16:00
6.34
+0.03
(+0.48%)
Pre-Market: 09:13
Aclaris Therapeutics Profit Margin (Quarterly) : -1.32K% for June 30, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.32K% |
| March 31, 2026 | -993.2% |
| December 31, 2025 | -1.53K% |
| September 30, 2025 | -443.0% |
| June 30, 2025 | -868.3% |
| March 31, 2025 | -1.04K% |
| December 31, 2024 | -1.05K% |
| September 30, 2024 | -174.6% |
| June 30, 2024 | -397.2% |
| March 31, 2024 | -706.5% |
| December 31, 2023 | -8.49% |
| September 30, 2023 | -315.2% |
| June 30, 2023 | -1.58K% |
| March 31, 2023 | -1.11K% |
| December 31, 2022 | -356.4% |
| September 30, 2022 | -104.9% |
| June 30, 2022 | -1.34K% |
| March 31, 2022 | -1.29K% |
| Date | Value |
|---|---|
| December 31, 2021 | -1.52K% |
| September 30, 2021 | -1.27K% |
| June 30, 2021 | -995.7% |
| March 31, 2021 | -1.62K% |
| December 31, 2020 | -860.6% |
| September 30, 2020 | -735.6% |
| June 30, 2020 | -565.5% |
| March 31, 2020 | -1.09K% |
| December 31, 2019 | -1.75K% |
| September 30, 2019 | -2.35K% |
| June 30, 2019 | -4.93K% |
| March 31, 2019 | -2.16K% |
| December 31, 2018 | -1.39K% |
| September 30, 2018 | -1.85K% |
| June 30, 2018 | -849.2% |
| March 31, 2018 | -2.70K% |
| December 31, 2017 | -2.30K% |
| September 30, 2017 | -2.66K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Corcept Therapeutics, Inc. | 16.45% |
| Nektar Therapeutics | -401.0% |
| Xeris Biopharma Holdings, Inc. | -33.77% |
| Crinetics Pharmaceuticals, Inc. | -481.1% |
| Alumis, Inc. | -8.56K% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -60.77% |
| Return on Assets | -41.91% |
| Return on Invested Capital | -59.76% |
| Gross Profit Margin (Quarterly) | 10.80% |
| Operating Margin (Quarterly) | -1.47K% |
| Return on Net Operating Assets | -1.03K% |